Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Purdue Feels The Pain With $700 Million Settlement For Misleading OxyContin Promos

This article was originally published in The Pink Sheet Daily

Executive Summary

Purdue pleads guilty to illegally promoting and selling the painkiller, ending an investigation by the U.S. Attorney’s Office in Virginia.

You may also be interested in...



Closing The Books On Purdue – And US FDA’s Policies To Control Opioids

A massive settlement of opioid litigation is intended to end the era of opioid marketing defined by OxyContin. It also like closes the books on efforts to rely on the US FDA to control the prescription abuse crisis.

Panel Abuses Purdue Over OxyContin

Tamper-resistant version would lead to more problems, say FDA advisors.

Panel Abuses Purdue Over OxyContin

Tamper-resistant version would lead to more problems, say FDA advisors.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel